PRESIDE(抑郁症药物基因组学)试验:在初级保健中,基于药物基因组学指导抗抑郁药处方对重度抑郁症患者抑郁结局影响的双盲随机对照试验
PRESIDE试验是一项分层双盲随机对照优效性试验,旨在评估在初级保健中提供药物基因组学指导的抗抑郁药处方报告(与使用澳大利亚治疗指南的标准处方相比)对12周后抑郁症状的影响。计划纳入672名18-65岁、PHQ-9评估为中重度抑郁症状、就诊于维多利亚州全科医生的患者,按1:1随机分配,患者和全科医生均设盲。主要结局为12周后PHQ-9抑郁症状变化在组间的差异。
要点
- 评估药物基因组学指导的抗抑郁药处方报告对初级保健中重度抑郁患者12周抑郁症状的影响。
- 计划纳入672名18-65岁中重度抑郁症状患者,按1:1随机分配至药物基因组学指导组或标准处方组。
- 主要结局为12周时PHQ-9抑郁症状变化在组间的差异,患者和全科医生均设盲。
核心结论
- 该试验将提供证据以判断药物基因组学指导的抗抑郁药处方是否具有临床疗效和成本效果。
- 该试验将为国家和国际政策与指南提供信息,指导在初级保健中为中重度抑郁症状患者使用药物基因组学选择抗抑郁药。
研究设计与样本
- PRESIDE试验是一项分层双盲随机对照优效性试验,在初级保健中开展。
- 计划纳入672名18-65岁、PHQ-9评估为中重度抑郁症状、就诊于维多利亚州全科医生的患者。
- 采用计算机生成的序列按1:1随机分配至药物基因组学指导的抗抑郁药处方报告组或使用澳大利亚治疗指南的标准处方组,患者和全科医生均设盲。
主要发现
- 主要结局为12周后PHQ-9抑郁症状变化在组间的差异。
- 次要结局包括第4、8和26周PHQ-9评分变化在组间的差异、12周缓解比例、抗抑郁药副作用特征变化、抗抑郁药依从性、生活质量变化以及干预的成本效果。
关键数值与推荐
- 现有指南涵盖使用药物基因组学检测指导13种抗抑郁药的处方。
- 既往针对抗抑郁药处方的药物基因组学检测随机对照试验显示与临床精神科设置中的抑郁缓解相关,但少有试验关注初级保健设置。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The evidence for the clinical utility of pharmacogenomic (PGx) testing is growing, and guidelines exist for the use of PGx testing to inform prescribing of 13 antidepressants. Although previous randomised controlled trials of PGx testing for antidepressant prescribing have shown an association with remission of depression in clinical psychiatric settings, few trials have focused on the primary care setting, where most antidepressant prescribing occurs. METHODS: The PRESIDE Trial is a stratified double-blinded randomised controlled superiority trial that aims to evaluate the impact of a PGx-informed antidepressant prescribing report (compared with standard prescribing using the Australian Therapeutic Guidelines) on depressive symptoms after 12 weeks, when delivered in primary care. Six hundred seventy-two patients aged 18-65 years of general practitioners (GPs) in Victoria with moderate to severe depressive symptoms, measured using the Patient Health Questionnaire-9 (PHQ-9), will be randomly allocated 1:1 to each arm using a computer-generated sequence. Participants and GPs will be blinded to the study arm. The primary outcome is a difference between arms in the change of depressive symptoms, measured using the PHQ-9 after 12 weeks. Secondary outcomes include a difference between the arms in change in PHQ-9 score at 4, 8 and 26 weeks, proportion in remission at 12 weeks, a change in side effect profile of antidepressant medications, adherence to antidepressant medications, change in quality of life and cost-effectiveness of the intervention. DISCUSSION: This trial will provide evidence as to whether PGx-informed antidepressant prescribing is clinically efficacious and cost-effective. It will inform national and international policy and guidelines about the use of PGx to select antidepressants for people with moderate to severe depressive symptoms presenting in primary care. TRIAL REGISTRATION: Australian and New Zealand Clinical Trial Registry ACTRN12621000181808. Registered on 22 February 2021.
引用
- Saya S, Chondros P, Abela A, et al. The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care. Trials. 2023. PMID: 37208772. doi:10.1186/s13063-023-07361-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。